Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving …

H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …

Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary …

H Watanabe, T Morimoto, M Natsuaki… - JAMA …, 2022 - jamanetwork.com
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials

S Cassese, RA Byrne, T Tada, LA King… - European heart …, 2012 - academic.oup.com
Aims The aim of this study was to evaluate benefits and risks of extending dual antiplatelet
therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era …

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis

P Xu, B Wang, Y Lu, QY Wu, ML Zhou, JR Wu, JJ Cai… - Bmj, 2019 - bmj.com
Objective To evaluate the efficacy and safety of standard term (12 months) or long term (> 12
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for …

PB Berger, DL Bhatt, V Fuster, PG Steg, KAA Fox… - Circulation, 2010 - Am Heart Assoc
Background—Uncertainty exists about the frequency, correlates, and clinical significance of
bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a …

Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis

SU Khan, M Singh, S Valavoor, MU Khan, AN Lone… - Circulation, 2020 - Am Heart Assoc
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …

Efficacy and safety of dual antiplatelet therapy after complex PCI

G Giustino, A Chieffo, T Palmerini, M Valgimigli… - Journal of the American …, 2016 - jacc.org
Background: Optimal upfront dual antiplatelet therapy (DAPT) duration after complex
percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear …

Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta …

S Benenati, M Galli, V De Marzo… - European Heart …, 2021 - academic.oup.com
Aim To provide an updated assessment of the efficacy–safety profile of very short (1 or 3
months) dual antiplatelet therapy (DAPT) compared with long (12 months) DAPT in patients …

Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

M Valgimigli, G Campo, M Monti, P Vranckx… - Circulation, 2012 - Am Heart Assoc
Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for
long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We …

An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial

M Natsuaki, H Watanabe, T Morimoto, K Yamamoto… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …